Business Context and Reporting Period
This Form 8-K was filed by Pieris Pharmaceuticals, Inc. (PIRS) on May 19, 2021. The report details a material definitive agreement entered into on the same date between Pieris Pharmaceuticals, Inc., its subsidiary Pieris Pharmaceuticals GmbH, and Genentech, Inc.
Key Financial Metrics and Transaction Value
The filing outlines a Research Collaboration and License Agreement focused on discovering, developing, and commercializing locally delivered respiratory and ophthalmology therapies using Pieris's Anticalin technology. Key financial terms include:
- Upfront Payment: $20 million to be received by Pieris.
- Milestone Payments: Eligibility for up to approximately $1.5 billion in additional payments across multiple programs.
- Royalties: Tiered royalty payments on net sales ranging from mid-single to low double-digits, subject to standard reductions.
- Program Milestones: Two initial programs are eligible for $11 million in preclinical milestones each.
- Expansion Option: Genentech may expand the collaboration to two additional programs for a $10 million fee per program.
The filing does not provide specific revenue, profit, cash flow, debt, or liquidity figures for the company's overall financial position.
Material Changes and Operational Roles
This agreement represents a significant strategic shift involving external partnership for development and commercialization.
- Pieris Responsibilities: Discovery research and early development of the two initial programs.
- Genentech Responsibilities: IND-enabling activities, clinical development, and commercialization of the programs.
- Scope: The collaboration excludes Pieris's internal programs.
Guidance, Risks, and Contract Terms
The agreement term continues until no royalty or payment obligations remain. Termination provisions include:
- Termination by either party for insolvency or uncured breach (90-day cure period).
- Termination by Genentech after 9 months from the effective date on a product-by-product or country-by-country basis.
- Notice periods for Genentech termination: 90 days prior to first commercial sale; 180 days after first commercial sale.
The full text of the Agreement is not included in this filing but is intended to be filed as an exhibit to the Form 10-Q for the quarter ending June 30, 2021.
Investor Verification Checklist
- Verify the receipt of the $20 million upfront payment in subsequent financial statements.
- Review the full Agreement text in the upcoming Form 10-Q for detailed royalty reduction clauses and offset mechanisms.
- Monitor the progress of the two initial programs to assess eligibility for the $11 million preclinical milestones.
- Track Genentech's exercise of the option to expand the collaboration to additional programs.